3-[2-(4,4-dimethylpiperidin-1-yl)ethoxy]-4-methoxyphenylamine | 777859-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[2-(4,4-dimethylpiperidin-1-yl)ethoxy]-4-methoxyphenylamine
• 英文别名: 3-[2-(4,4-dimethylpiperidin-1-yl)ethoxy]-4-methoxyaniline
• CAS: 777859-95-7
• 化学式: C₁₆H₂₆N₂O₂
• 分子量: 278.395
• InChiKey: QONBBORKQXQEOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  47.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[2-(4,4-dimethylpiperidin-1-yl)ethoxy]-4-methoxyphenylamine 、 2-(3,4-dichloro-phenyl)-pent-4-enoyl chloride 在 TEA 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: Synthesis and biological evaluation

  摘要：

  Within the continuous quest for the discovery of novel compounds able to treat anxiety and depression, the generation of a pharmacophore model for 5-HT2C receptor antagonists and the discovery of a new class of potent and selective 5-HT2C molecules are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.034
• 作为产物：
  描述：

  1-[2-(2-methoxy-5-nitrophenoxy)ethyl]-4,4-dimethylpiperidine 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give 328 mg of the title compound as a pink oil的产率得到3-[2-(4,4-dimethylpiperidin-1-yl)ethoxy]-4-methoxyphenylamine
  参考文献：
  名称：

  Compounds having activity at 5ht2c receptor and uses thereof

  摘要：

  公开了公式（I）的化合物及其药学上可接受的盐：其中，R1是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷基硫基，羟基，氨基，单取代或双取代C1-6烷基氨基，N-连接的4至7成员杂环基，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，-COOR3，-COR4，其中R3和R4独立地是氢或C1-6烷基，或-COR5，其中R5是氨基，单取代或双取代C1-6烷基氨基或N-连接的4至7成员杂环基；p为0、1、2或3；Q为6成员芳香基或6成员杂芳基；A为-(CH2-CH2)-、-(CH═CH)-或一个基团-(CHR7)-，其中R7为氢、卤素、羟基、氰基、硝基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基或C1-6烷基硫基；R2为氢、卤素、羟基、氰基、硝基、C1-6烷基、C1-6烷酰基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基、氨基、单取代或双取代C1-6烷基氨基或N-连接的4至7成员杂环基；X为氧、硫、-CH2-或NR8，其中R8为氢或C1-6烷基；Y为单键、-CH2-、-(CH2)2-或-CH═CH-；Z为可选取代的N-连接的杂环基或含有至少一个氮的C-连接的4至7成员杂环基，或Z为-NR9R10，其中R9和R10独立地为氢或C1-6烷基。还公开了制备方法及其在治疗中的用途，例如用于抑郁症或焦虑症。

  公开号：

  US20070191457A1

文献信息

• [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE PAR RAPPORT AU RECEPTEUR 5HT2C ET LEURS APPLICATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2004089897A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, -COOR3, -COR4 (wherein R3 and R4, are independently hydrogen or C1-6alkyl) or -COR5 (wherein R5 is amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group); p is 0, 1 or 2 or 3; Q is a 6- membered aromatic group or a 6-membered heteroaromatic group; A is -(CH2-CH2)-, -(CH=CH)-, or a group -(CHR7)- wherein R7 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1 6alkylthio; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1 6alkylthio, amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.

  公开了具有式（I）的化合物及其药学上可接受的盐：其中R1是卤素、氰基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、C1-6烷氧基、C1-6烷基硫基、羟基、氨基、单取代或双取代的C1-6烷基氨基、N-连接的4至7成员杂环基、硝基、卤代C1-6烷基、卤代C1-6烷氧基、芳基、-COOR3、-COR4（其中R3和R4独立地是氢或C1-6烷基）或-COR5（其中R5是氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基）；p为0、1、2或3；Q为6-成员芳基或6-成员杂芳基；A为-(CH2-CH2)-、-(CH=CH)-或一个基团-(CHR7)-其中R7是氢、卤素、羟基、氰基、硝基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基或C1-6烷基硫基；R2是氢、卤素、羟基、氰基、硝基、C1-6烷基、C1-6烷酰基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基、氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基；X是氧、硫、-CH2-或NR8其中R8是氢或C1-6烷基；Y是单键、-CH2-、-(CH2)2-或-CH=CH-；Z是一个可选择取代的N-连接杂环基或含有至少一个氮的C-连接的4至7成员杂环基，或Z是-NR9R10其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法和在治疗中的用途，例如用于抑郁症或焦虑症。
• Compounds having activity at 5ht2c receptor and uses thereof
  申请人：Bonanomi Giorgio

  公开号：US20070191457A1

  公开（公告）日：2007-08-16

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R 1 is halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC 1-6 alkyl, haloC 1-6 alkoxy, aryl, —COOR 3 , —COR 4 , wherein R 3 and R 4 are independently hydrogen or C 1-6 alkyl, or —COR 5 , wherein R 5 is amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; p is 0, 1, 2 or 3; Q is a 6-membered aromatic group or a 6-membered heteroaromatic group; A is —(CH 2 —CH 2 )—, —(CH═CH)—, or a group —(CHR 7 )— wherein R 7 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or C 1-6 alkylthio; R 2 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 1-6 alkanoyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, —CH 2 — or NR 8 wherein R 8 is hydrogen or C 1-6 alkyl; Y is a single bond, —CH 2 —, —(CH 2 ) 2 — or —CH═CH—; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is —NR 9 R 10 where R 9 and R 10 are independently hydrogen or C 1-6 alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.

  公开了公式（I）的化合物及其药学上可接受的盐：其中，R1是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷基硫基，羟基，氨基，单取代或双取代C1-6烷基氨基，N-连接的4至7成员杂环基，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，-COOR3，-COR4，其中R3和R4独立地是氢或C1-6烷基，或-COR5，其中R5是氨基，单取代或双取代C1-6烷基氨基或N-连接的4至7成员杂环基；p为0、1、2或3；Q为6成员芳香基或6成员杂芳基；A为-(CH2-CH2)-、-(CH═CH)-或一个基团-(CHR7)-，其中R7为氢、卤素、羟基、氰基、硝基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基或C1-6烷基硫基；R2为氢、卤素、羟基、氰基、硝基、C1-6烷基、C1-6烷酰基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基、氨基、单取代或双取代C1-6烷基氨基或N-连接的4至7成员杂环基；X为氧、硫、-CH2-或NR8，其中R8为氢或C1-6烷基；Y为单键、-CH2-、-(CH2)2-或-CH═CH-；Z为可选取代的N-连接的杂环基或含有至少一个氮的C-连接的4至7成员杂环基，或Z为-NR9R10，其中R9和R10独立地为氢或C1-6烷基。还公开了制备方法及其在治疗中的用途，例如用于抑郁症或焦虑症。
• COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF
  申请人：GLAXO GROUP LIMITED

  公开号：EP1611098B1

  公开（公告）日：2006-12-27
• EP1611098A1
  申请人：——

  公开号：EP1611098A1

  公开（公告）日：2006-01-04
• Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: Synthesis and biological evaluation
  作者：Fabrizio Micheli、Alessandra Pasquarello、Giovanna Tedesco、Dieter Hamprecht、Giorgio Bonanomi、Anna Checchia、Albert Jaxa-Chamiec、Federica Damiani、Silvia Davalli、Daniele Donati、Chiara Gallotti、Marcella Petrone、Marilisa Rinaldi、Graham Riley、Silvia Terreni、Martyn Wood

  DOI：10.1016/j.bmcl.2006.05.034

  日期：2006.8

  Within the continuous quest for the discovery of novel compounds able to treat anxiety and depression, the generation of a pharmacophore model for 5-HT2C receptor antagonists and the discovery of a new class of potent and selective 5-HT2C molecules are reported. (c) 2006 Elsevier Ltd. All rights reserved.